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Original Investigation | Oncology

Association of Cumulative Social Risk and Social Support With Receipt
of Chemotherapy Among Patients With Advanced Colorectal Cancer
Rachel E. Davis, PhD; Amber W. Trickey, PhD; Paul Abrahamse, MA; Ikuko Kato, PhD; Kevin Ward, PhD; Arden M. Morris, MD

Abstract
IMPORTANCE Approximately 38% of patients with advanced colorectal cancer do not receive
chemotherapy.
OBJECTIVE To determine whether cumulative social risk (ie, multiple co-occurring
sociodemographic risk factors) is associated with lower receipt of chemotherapy among patients
with advanced colorectal cancer and whether social support would moderate this association.

Key Points
Question Is cumulative social risk (ie,
co-occurring sociodemographic
barriers) associated with lower receipt
of chemotherapy among patients with
advanced colorectal cancer, and does
social support moderate this
association?

DESIGN, SETTING, AND PARTICIPANTS This cross-sectional, population-based, mailed survey

Findings Data from a cross-sectional

study was conducted from 2012 to 2014. Participants were recruited between 2011 and 2014 from all

survey of 1087 diverse adults with stage

adults within 1 year after diagnosis of stage III colorectal cancer in the Detroit, Michigan, and State of

III colorectal cancer indicated that

Georgia Surveillance, Epidemiology, End-Results cancer registries. Patients were eligible if they were

participants with 3 or more social risk

aged 18 years or older, had undergone surgery 4 or more months ago, did not have stage IV cancer,

factors were less likely to receive

and resided in the registry catchment areas. Data analyses were conducted from March 2017 to

chemotherapy than participants with 0

April 2021.

risk factors. The association of
cumulative social risk with

MAIN OUTCOMES AND MEASURES The primary outcome was receipt of chemotherapy.

chemotherapy receipt was moderated

Cumulative social risk represented a sum of 8 risk factors with the potential to drain resources from

by access to social support.

participants’ cancer treatment (marital status, employment, annual income, health insurance,
comorbidities, health literacy, adult caregiving, and perceived discrimination). Social support was
operationalized as emotional support related to colorectal cancer diagnosis.

Meaning These findings suggest that
assessing cumulative social risk may
identify patients with advanced
colorectal cancer who are at higher risk

RESULTS Surveys were mailed to 1909 eligible patients; 1301 completed the survey (response rate,

for omitting chemotherapy.

68%). A total of 1087 participants with complete data for key variables were included in the sample
(503 women [46%]; mean [SD] age, 64 [13] years). Participants with 3 or more risk factors were less
likely to receive chemotherapy than participants with 0 risk factors (3 factors, odds ratio [OR], 0.48
[95% CI, 0.26-0.87]; 4 factors, OR, 0.41 [95% CI, 0.21-0.78]; 5 factors, OR, 0.42 [95% CI, 0.20-0.87];
ⱖ6 factors, OR, 0.22 [95% CI, 0.09-0.55]). Participants with 2 or more support sources had higher
odds of undergoing chemotherapy than those without social support (2 sources, OR, 3.05 [95% CI,
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1.36-6.85]; 3 sources, OR, 3.24 [95% CI, 1.48-7.08]; 4 sources, OR, 3.69 [95% CI, 1.71-7.97]; 5 sources,
OR, 4.40 [95% CI, 1.98-9.75]; ⱖ6 sources, OR 5.95 [95% CI, 2.58-13.74]). Within each social support
level, participants were less likely to receive chemotherapy as cumulative social risk increased.
CONCLUSIONS AND RELEVANCE Cumulative social risk was associated with reduced receipt of
chemotherapy. These associations were mitigated by social support. Assessing cumulative social risk
may identify patients with colorectal cancer who are at higher risk for omitting chemotherapy who
can be targeted for support programs to address social disadvantage and increase social support.
JAMA Network Open. 2021;4(6):e2113533. doi:10.1001/jamanetworkopen.2021.13533
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Introduction
Adjuvant chemotherapy after surgery among patients with stage III colorectal cancer (CRC) is
associated with up to a 30% increase in 5-year survival rates.1-3 Yet, among the 40 000 US
individuals with recent diagnoses of stage III CRC,4 approximately 38% will not receive adjuvant
chemotherapy, with no discernable clinical rationale.5-8 Patients need resources to accommodate the
physical, financial, cognitive, and emotional demands of chemotherapy, and health, demographic,
and social factors may deter chemotherapy initiation among patients with CRC. Older patients with
extensive comorbid disease are more likely to experience delays or omission of chemotherapy, even
absent clinical concerns. With few exceptions,9,10 studies have found lower rates of chemotherapy
receipt among Black patients compared with White patients with CRC, perhaps because of economic
and social disadvantage.6,11-16 Patients with lower income or health literacy levels are also less likely
to receive chemotherapy.11,17-20 The association of perceived discrimination, owing to race or other
characteristics, with chemotherapy or other treatment uptake are unknown, but previous studies
suggest that there is an association between discrimination and reduced CRC screening.21,22 To our
knowledge, no preexisting research has examined the cumulative associations of multiple,
co-occurring social risk factors with chemotherapy receipt for CRC, which may serve as more
powerful deterrents than a single barrier alone.
In contrast, social support appears to have a beneficial association with chemotherapy receipt.
Married patients with CRC have higher rates of chemotherapy receipt,11,13,15 fewer delays in starting
chemotherapy,19 and greater likelihood of completing chemotherapy than single adults.15 Studies
outside the US indicate that social support is associated with stress reduction during
chemotherapy,23 completion of chemotherapy,24 and overall and CRC-specific survival.25 More
research is needed to examine the associations of social support with chemotherapy receipt among
patients with CRC in the US.
This survey study sought to examine whether cumulative social risk was associated with lower
use of chemotherapy among patients with advanced CRC. On the basis of the buffering model, which
predicts that the adverse effects of stress may be reduced by social support,26 we further
hypothesized that social support would mitigate the association between cumulative social risk and
chemotherapy receipt.

Methods
The study protocol was approved by institutional review boards at the University of Michigan, Wayne
State University, Emory University, the State of Michigan, and the State of Georgia. In keeping with
study participant deidentification protocols, all relevant institutional review boards granted a waiver
of written informed consent. This study follows the American Association for Public Opinion
Research (AAPOR) reporting guideline.

Questionnaire Development
The questionnaire was specifically developed to focus on experiences with CRC and was based on
well-described conceptual frameworks, including the Mandelblatt27 and Andersen28 models of
equity in access to and use of care. Through an extensive literature review, we identified and included
existing, validated instruments that captured the relevant domains whenever possible. As
appropriate, these instruments were modified to refer specifically to experiences with the diagnosis
and treatment of CRC. When preexisting measures were unavailable, the study team generated
questions based on preliminary focus group data. A nearly final version of the questionnaire was
cognitively pretested among patients who would have been eligible to participate but were not
included. On the basis of their responses, we iteratively modified and repeat tested the survey until
the survey items and respondent burden stabilized.
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Participants
All eligible adults who had received a diagnosis of stage III CRC within 1 year, between August 2011
and December 2014, were identified in the Detroit, Michigan, tri-county area and the State of Georgia
Surveillance, Epidemiology, End-Results (SEER) cancer registries using Rapid Case Ascertainment.
Patients were eligible if they were aged 18 years or older, had undergone surgery at least 4 months
ago, did not have stage IV cancer, and resided in the targeted SEER catchment areas.

Data Collection
After allowing physician opt-out, patients were invited to participate in a self-administered mailed
survey, which included a $10 preincentive and up to 9 multimodal contact attempts.29 Completed
questionnaires were accepted up to 1 year after surgery. Participants were recontacted, as necessary,
to clarify responses or obtain missing information. The overall survey response rate was calculated
in accordance with American Association for Public Opinion Research30 standards as the number of
unique surveys that were completed and returned by eligible patients divided by the total number of
eligible patients. The total number of eligible patients was the sum of those who returned surveys,
refused participation, could not be located, or were prohibited from participation by the physician
of record.

Measures
Receipt of Chemotherapy
The standard of care for treatment of stage III CRC during the study period included initiation of
chemotherapy within 4 months after surgery. Receipt of chemotherapy was defined as a yes
response to the question, “Did you or are you going to have chemotherapy to treat your colorectal
cancer?” and a yes or “I’m still receiving chemotherapy treatment” response to the question, “Did you
have ALL of the chemotherapy treatments that were first planned?” Nonreceipt of chemotherapy
was defined a no or “I have not started chemotherapy treatment” response, indicating no initiation of
chemotherapy within 4 months of surgery. Initiation of chemotherapy more than 4 months
postoperatively no longer confers a survival advantage for stage III CRC and is no longer
recommended.31,32
Cumulative Social Risk
Cumulative social risk represented positive responses to questions assessing 8 social risk factors with
the potential to drain time, energy, financial, or other resources from cancer treatment. In the
interests of clarity and the absence of literature to guide assigning weights to social risk, we decided
a priori to dichotomize. Accordingly, each social risk factor was assigned a value of 1, indicating the
presence of higher risk, and a value of 0, indicating lower risk, with a summative range of 0 to 8.
However, because no participants reported 8 factors and only 11 participants reported 7 factors, the
6 to 8 categories were collapsed, yielding a final variable with values ranging from 0 to 6 or more,
with higher scores indicating increased cumulative social risk. The following risk factors were
included: marital status, employment, income, health insurance, comorbidities, health literacy, adult
caregiving, and perceived discrimination.
For marital status, participants who were married or living with a partner were assigned a risk
value of 0. All others were assigned a 1.
For employment, participants who were unemployed or disabled at the time of the survey were
assigned a 1. All others were assigned a 0.
For income, participants reported their annual household income at diagnosis (<$20 000,
$20 000-$49 999, $50 000-$89 999, and ⱖ$90 000), with multiple imputation used to estimate
income from respondents’ demographic data (age, sex, race, education, and marital status) for 246
respondents with missing data. Participants with an annual income of $50 000 or higher, or
approximately twice the Federal Poverty Level for a family of 4, were assigned a 0, whereas all others
were assigned a 1.
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For health insurance, participants with Medicaid or no insurance at diagnosis were assigned a 1,
and participants with Medicare, private insurance, or other insurance were assigned a 0. If data were
missing, responses to an item querying employer-provided benefits at diagnosis were reviewed, and
participants with health insurance benefits were coded as 0. If responses to both items were missing,
the risk score was based on a question assessing insurance status at the time of the survey.
For comorbidities, 10 items queried whether participants had been told by a doctor that they
had chronic bronchitis or emphysema, heart disease, cancer (not skin cancer or CRC), diabetes,
gastrointestinal problems (eg, irritable bowel syndrome), high blood pressure, stroke, liver disease;
kidney failure, or depression. On the basis of previous work from our group and others33,34 indicating
progressively diminishing association with outcomes when adjusting for 2 or more comorbidities,
participants were assigned a 1 if they reported 2 or more comorbidities and a 0 for 1 or fewer
comorbidities.
Health literacy was represented by the mean of 3 items previously validated in clinical
populations,35,36 which were slightly adapted to focus on difficulties understanding their CRC or CRC
treatment. Participants who said they never or occasionally had difficulty on all 3 items were
categorized as having adequate health literacy and assigned 0. All others were categorized as having
inadequate or marginal health literacy and were assigned a 1.
With regard to adult caregiving, participants who assisted another adult who lived in their home
with personal care were assigned a 1. All others were assigned a 0.
For perceived discrimination, 10 items adapted from the Everyday Discrimination Scale37,38
gauged how often participants experienced perceived discrimination in their everyday lives
according to age, sex, race/ethnicity, religion, marital status, sexual orientation, weight, income,
education, and speech. Participants who had never experienced discrimination were assigned a 0; all
others were assigned a 1. This coding was consistent with other research,39 acknowledging that even
a single experience with discrimination may be traumatic and have long-lasting effects.
Social Support
A 7-item scale queried how much emotional support participants had received since diagnosis from
7 sources: spouse or partner, other family members, friends, health care practitioners, coworkers,
religious community, or other people with CRC.40 Responses of quite a bit or a lot were coded as 1,
whereas responses of none, a little, some, or does not apply and missing data were coded as 0. The
codes were summed to represent the number of sources of social support. The top 2 categories were
collapsed into 6 or more for analysis.
Sociodemographic Variables
Single-item measures of sex (male/female), age (25-49, 50-64, and ⱖ65 years), and race (Black and
White) were modeled as covariates. Race was included as a covariate because it is independently
associated with receipt of chemotherapy. Education was assessed to describe the cohort.
Sociodemographic variables were self-identified by participants using the categories provided in the
survey instrument.

Statistical Analysis
Descriptive statistics were calculated for the primary variables. Cumulative social risk and social
support were compared by race, sex, and site using 2-sided Wilcoxon rank-sum tests and across age
groups using 2-sided Kruskal-Wallis tests. Logistic regression was used to assess the associations of
cumulative social risk and social support with chemotherapy receipt.
We first fit a model including cumulative social risk as the primary independent variable while
adjusting for age, sex, and race. We then added social support to determine whether associations
between chemotherapy receipt and cumulative social risk persisted after adjusting for social support.
Finally, to evaluate whether cumulative social risk had a diminished association with chemotherapy
treatment when social support was high, we assessed for a moderating association with an
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interaction term (cumulative social risk × social support) in the logistic regression model using 2
approaches: (1) a continuous interaction between the number of social risk factors and the number
of sources of social support, each representing 0 to 6 or more, and (2) a dichotomous 2 × 2
interaction with cumulative social risk and social support dichotomized at the medians. The
parsimonious model was then selected. The final model included categorical variables for cumulative
social risk and social support to estimate the marginal associations of the number of sources of social
support on chemotherapy receipt at each level of cumulative social risk with 95% CIs using Stata/MP
statistical software version 14.2 (StataCorp). Statistical significance was set at P < .05.
In all sensitivity analyses, we used a decision process guided by the level of missingness in the
independent variables. All component social risk variables had missing data for less than 5% of
participants, suggesting potentially negligible missing data. Following these practical guidelines, we
used the observed data (complete cases) in the main analysis. We did not include respondents who
were missing data necessary to calculate the social risk score (110 of 1203 respondents). To estimate
the uncertainty due to missingness in these variables, we performed missing data sensitivity analyses
as recommended by Jakobsen et al41: best-worst case and worst-best case imputation analyses. We
found strikingly similar results and model classification performance in the sensitivity analyses,
suggesting that the missing data may be ignored (eTable 1 in the Supplement).
To ensure generalizability, we determined variable-specific nonresponse rates using a logistic
regression of survey response with those covariates and used the inverse probabilities from that
model as the survey weights. We then created additional weights based on these variables to reflect
the difference between Rapid Case Ascertainment patients available for survey and the larger
population of all patients with stage III CRC in Georgia and Detroit. The final weights are equal to the
product of those 2 weighting components and were then standardized so the weighted
number equals the unweighted number. We performed sensitivity analyses using the survey weights
for the final models (eTable 2 in the Supplement). Data analyses were conducted from March 2017
to April 2021.

Results
We identified 2168 patients with an incident diagnosis of stage III CRC reported to the SEER registries
of Georgia and Detroit using Rapid Case Ascertainment. Among these, 259 (12%) were later
determined to be ineligible because they had metastatic disease, noncolorectal primary cancer, a
previous cancer diagnosis, or residence outside the registry catchment area. Among 1909 eligible
patients included in the final sample, 608 could not be located or did not return the survey, leaving
1301 patients (68% survey response rate). The current study is restricted to the 1087 respondents
who provided complete social risk information. The sample was almost half women (503 women
[46%]), mostly White (802 participants [74%]), and had a mean [SD] age of 64 [13] years (Table 1).
Twenty-two percent of respondents had not received chemotherapy. The mean (SD) number of
social risk factors was 2.46 (1.61). The mean (SD) number of sources of social support was 3.97 (1.69).

Social Risk
Participants who were women (median [interquartile range {IQR}] social risk factors, 3 [2-4]), aged
50 years or older (median [IQR] social risk factors, 2 [1-4] for those aged 50-64 years and 3 [1-3] for
those aged ⱖ65 years), or who identified as Black individuals (median [IQR] social risk factors, 3
[3-4]) had a higher cumulative social risk than those who were younger (median [IQR] social risk
factors for those aged 25-49 years, 2 [1-4]), White individuals (median [IQR] social risk factors, 2
[1-3]), or men (median [IQR] social risk factors, 2 [1-3]) (Table 2). Having 1 or 2 risk factors was not
associated with reduced chemotherapy receipt (Table 3, model 1); however, participants with 3
(odds ratio [OR] 0.48; 95% CI, 0.26-0.87; P = .02), 4 (OR, 0.41; 95% CI, 0.21-0.78; P = .007), 5 (OR,
0.42; 95% CI, 0.20-0.87; P = .02), or 6 or more (OR, 0.22; 95% CI, 0.09-0.55; P = .001) risk factors
were significantly less likely to receive chemotherapy than participants with 0 risk factors. Older age
JAMA Network Open. 2021;4(6):e2113533. doi:10.1001/jamanetworkopen.2021.13533 (Reprinted)
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(ⱖ65 years) was also associated with lower likelihood of chemotherapy receipt (OR, 0.28; 95% CI,
0.16-0.49; P < .001).

Social Support
Participants reported receiving CRC-related social support from family members other than spouses
or partners (939 participants [86%]), followed by friends (842 participants [77%]), health care
practitioners (734 participants [68%]), spouses or partners (709 participants [65%]), members of

Table 1. Descriptive Statistics for the Study Sample of Patients With Colorectal Cancer
Characteristic

Patients, No. (%)
(N = 1087)

Sex
Female

503 (46)

Male

584 (54)

Age, mean (SD), y

64 (13)

Race
White

802 (74)

Black

285 (26)

Education
Less than high school, high school graduate, or general equivalency diploma

442 (41)

Some college or technical school

358 (33)

4-y college graduate or graduate degree

285 (26)

Study site
Georgia
Detroit, Michigan
Receipt of chemotherapy as intended

701 (64)
386 (36)
845 (78)

Social risk factors
Marital status
Married or living with a partner (risk = 0)

655 (60)

Never married, separated, divorced, widowed (risk = 1)

432 (40)

Employment status
Working part-time, working full-time, homemaker, student, retired (risk = 0)

821 (76)

Unemployed or disabled (risk = 1)

266 (24)

Annual household income, $
≥50 000 (risk = 0)

473 (44)

<50 000 (risk = 1)

614 (56)

Health insurance
Private insurance or Medicare (risk = 0)

902 (83)

Medicaid or no insurance (risk = 1)

185 (17)

Comorbidities (in addition to CRC)
0 or 1 comorbidities (risk = 0)

593 (55)

≥2 comorbidities (risk = 1)

494 (45)

Health literacy
Adequate (risk = 0)

938 (86)

Marginal or inadequate (risk = 1)

149 (14)

Adult caregiving
Does not provide caregiving for another adult (risk = 0)

935 (86)

Provides care for at least 1 spouse, parent, parent-in-law, adult relative,
or friend who lives in the participant’s home (risk = 1)

152 (14)

Perceived discrimination
Never (risk = 0)

706 (65)

Rarely, sometimes, often, or very often (risk = 1)

381 (35)

Social risk factors, mean (SD), No.

2.46 (1.61)

Sources of social support, mean (SD), No.

3.97 (1.69)
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their religious communities (526 participants [48%]), coworkers (331 participants [30%]), and other
people with CRC (236 participants [22%]) (eTable 3 in the Supplement). Participants who were
younger (median [IQR] sources of social support for those aged 25-49 years, 5 [3-6]) and White
participants (median [IQR] sources of social support, 4 [3-5]) reported more social support than
those who were older (median [IQR] sources of social support, 4 [3-5.5] for those aged 50-64 years
and 4 [2-5] for those aged ⱖ65 years) and Black participants (median [IQR] sources of social support,
4 [2-5]). Social support was also independently associated with chemotherapy receipt: participants
who reported 2 or more sources of social support were more likely to receive chemotherapy than
participants with no support (2 sources, OR, 3.05 [95% CI, 1.36-6.85]; 3 sources, OR, 3.24 [95% CI,
1.48-7.08]; 4 sources, OR, 3.69 [95% CI, 1.71-7.97]; 5 sources, OR, 4.40 [95% CI, 1.98-9.75]; ⱖ6
sources, OR 5.95 [95% CI, 2.58-13.74]).

Cumulative Social Risk and Social Support
Adding social support to the model reduced the association of cumulative social risk on
chemotherapy receipt (Table 3, model 2). Although participants with 4 (OR, 0.50; 95% CI 0.26-0.97;
P = .04) or 6 or more (OR, 0.32; 95% CI, 0.12-0.84; P = .02) risk factors were still less likely than
participants with 0 risk factors to undergo chemotherapy, the associations of cumulative social risk
were reduced when adjusting for social support. As in model 1, older age was associated with lower
likelihood of chemotherapy receipt (age ⱖ65 years, OR, 0.32; 95% CI, 0.18-0.57; P < .001).
Interactions between cumulative social risk and social support were not significant when modeled as
continuous or dichotomous variables.
Although most participants received chemotherapy, within each level of social support,
participants were generally less likely to receive chemotherapy as the number of social risk factors
increased (Figure). For example, among those with no social support, the probability of receiving
chemotherapy was approximately 60% for participants with 0 risk factors, less than 50% for
participants with 3 or more risk factors, and less than 40% for those with 6 or more risk factors.
Among participants with 6 or more sources of social support, the probability of receiving
chemotherapy decreased from almost 90% for those with 0 risk factors to approximately 75% for
those with 6 or more risk factors.
To examine which social risk and social support factors may have been most influential,
associations between individual factors and chemotherapy receipt are displayed in Table 4. Marginal
or inadequate health literacy (OR, 0.45; 95% CI, 0.31-0.66; P < .001), annual income less than
$50 000 (OR, 0.55; 95% CI, 0.40-0.77; P < .001), single marital status (OR, 0.64; 95% CI, 0.46-0.87;

Table 2. Cumulative Social Risk and Social Support by Sex, Age, Race, and Site

Characteristic

Participants, No.
(N = 1087)

Social risk factors, No.

Sources of social support, No.

Median (IQR)

Mean (SD)

P valuea

Median (IQR)

Mean (SD)

4 (3-5)

4.02 (1.70)

4 (3-5)

3.91 (1.70)

P value

Sex
Male

584

2 (1-3)

2.27 (1.60)

Female

503

3 (2-4)

2.68 (1.60)

25-49

143

2 (1-4)

2.17 (1.90)

5 (3-6)

4.51 (1.60)

50-64

404

2 (1-4)

2.51 (1.70)

4 (3-5.5)

4.25 (1.60)

≥65

540

3 (1-3)

2.49 (1.40)

4 (2-5)

3.62 (1.70)

White

802

2 (1-3)

2.11 (1.50)

4 (3-5)

4.04 (1.60)

Black

285

3 (3-4)

3.44 (1.40)

4 (2-5)

3.76 (1.80)

Detroit, Michigan

386

3 (1-4)

2.57 (1.60)

4 (3-5)

3.58 (1.70)

Georgia

701

2 (1-4)

2.40 (1.60)

4 (3-5)

4.19 (1.70)

<.001

.34

Age, y

.04

<.001

Race
<.001

.04

Site
.14

<.001

Abbreviation: IQR, interquartile range.
a

The P values in this table were obtained from Wilcoxon rank-sum tests for sex, race, and site, and Kruskal-Wallis tests for age.
JAMA Network Open. 2021;4(6):e2113533. doi:10.1001/jamanetworkopen.2021.13533 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a University of South Carolina User on 04/25/2022

June 9, 2021

7/14

JAMA Network Open | Oncology

Association of Social Risk and Social Support With Chemotherapy Use for Patients With Advanced CRC

P = .005), and perceived discrimination (OR, 0.73; 95% CI, 0.53-0.997; P = .048) were each
associated with decreased odds of receiving chemotherapy. When we controlled for age, sex, race,
and site, additional analyses further indicated that receiving social support from coworkers (OR,
Table 3. Logistic Regression Estimates of the Association of Cumulative Social Risk and Social Support
With Receipt of Chemotherapy
Participants,
No.
(N = 1087)

Model 1
OR (SE) [95% CI]

P value

OR (SE) [95% CI]

0

137

1 [Reference]

NA

[Reference]

NA

1

197

1.04 (0.35) [0.54-2.00]

.90

1.06 (0.36) [0.55-2.05]

.87

2

228

0.71 (0.22) [0.39-1.31]

.28

0.79 (0.25) [0.42-1.46]

.44

3

245

0.48 (0.15) [0.26-0.87]

.02

0.56 (0.17) [0.30-1.03]

.06

4

160

0.41 (0.13) [0.21-0.78]

.007

0.50 (0.17) [0.26-0.97]

.04

5

86

0.42 (0.16) [0.20-0.87]

.02

0.54 (0.21) [0.25-1.14]

.11

≥6

34

0.22 (0.10) [0.09-0.55]

.001

0.32 (0.16) [0.12-0.84]

.02

0

35

NA

NA

[Reference]

NA

1

61

NA

NA

1.94 (0.87) [0.80-4.68]

.14

2

119

NA

NA

3.05 (1.26) [1.36-6.85]

.007

3

176

NA

NA

3.24 (1.29) [1.48-7.08]

.003

4

260

NA

NA

3.69 (1.45) [1.71-7.97]

.001

5

221

NA

NA

4.40 (1.79) [1.98-9.75]

<.001

≥6

215

NA

NA

5.95 (2.54) [2.58-13.74]

<.001

Black

285

1 [Reference]

NA

1 [Reference]

NA

White

802

0.84 (0.16) [0.58-1.21]

.34

0.83 (0.16) [0.57-1.20]

.32

25-49

143

1 [Reference]

NA

1 [Reference]

NA

50-64

404

0.97 (0.30) [0.53-1.79]

.93

1.01 (0.32) [0.55-1.86]

.98

≥65

540

0.28 (0.08) [0.16-0.49]

<.001

0.32 (0.09) [0.18-0.57]

<.001

Female

503

1 [Reference]

NA

1 [Reference]

NA

Male

584

0.91 (0.14) [0.67-1.24]

.55

0.90 (0.14) [0.66-1.23]

.53

701

1 [Reference]

NA

]1 [Reference]

NA

Variable

Model 2
P value

Cumulative social risk

Sources of social
support, No.

Race

Age, y

Sex

Site
Georgia

Abbreviations: NA, not applicable; OR, odds ratio.
a

Detroit, Michigan
Intercepta

386

0.90 (0.14) [0.66-1.22]

.48

1.01 (0.16) [0.74-1.39]

.93

NA

15.62 (6.32) [7.07-34.52]

<.001

3.42 (1.88) [1.16-10.04]

.03

The intercept represents the log odds of receiving
chemotherapy for patients with characteristics at the
covariate referent category levels.

Figure. Probability of Receiving Chemotherapy by Cumulative Social Risk and Social Support
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2.60; 95% CI, 1.70-3.98; P < .001), health care practitioners (OR, 1.97; 95% CI, 1.45-2.68; P < .001),
friends (OR, 1.83; 95% CI, 1.32-2.55; P < .001), spouses or partners (OR, 1.73; 95% CI, 1.25-2.38;
P = .001), and family members (OR, 1.63; 95% CI, 1.10-2.41; P = .02) were each associated with
increased odds of receiving chemotherapy.

Discussion
In this population-based survey study, we found that patients with advanced CRC and higher
cumulative social risk were less likely than their counterparts with lower social risk to receive
adjuvant chemotherapy. Specifically, having 3 or more social risk factors significantly decreased the
odds that patients with CRC would receive chemotherapy. The social risk factors most associated
with decreased likelihood of chemotherapy receipt included lower health literacy, the lack of a
spouse or partner, lower household income, and perceived discrimination. The association of
cumulative social risk with chemotherapy receipt was mitigated, however, if patients had strong
social support during their CRC treatment. Most participants, regardless of cumulative risk or social
support, reported undergoing chemotherapy. However, within each level of social support, we
observed a consistent pattern whereby patients with more cumulative social risk were generally less
likely to initiate chemotherapy treatment per guideline recommendations.
Previous research on factors associated with chemotherapy receipt among patients with CRC
has primarily examined the association of sociodemographic barriers in isolation or in combination
with race. However, such analyses may not adequately characterize the complexity of the barriers
that socioeconomically vulnerable patients face, because patients from such populations are likely to
experience multiple risk factors simultaneously.42 Although, to our knowledge, no studies have
examined the association of cumulative social risk with receipt of chemotherapy, a study43 of Black
patients with CRC who had no or inadequate health insurance or who lived in high-poverty
neighborhoods found that they were 20% less likely to receive chemotherapy than White patients

Table 4. Associations Between Individual Social Risk Factors and Social Support and Receipt of Chemotherapy
for 1087 Patients With CRCa
Variables

OR (95% CI)

P value

Social risk factors
Health literacy: marginal or inadequate health literacy (reference, adequate)

0.45 (0.31-0.66)

<.001

Annual household income: <$50 000 (reference, ≥$50 000)

0.55 (0.40-0.77)

<.001

Marital status: never married, separated, divorced, or widowed (reference,
married or living with a partner)

0.64 (0.46-0.87)

.005

Experiences of everyday discrimination: rarely, sometimes, often, or very often
(reference, never)

0.73 (0.53-0.997)

.048

Employment status: unemployed or disabled (reference, working part-time,
working full-time, homemaker, student, or retired)

0.80 (0.54-1.20)

.29

Health insurance: Medicaid or no insurance (reference, private insurance or
Medicare)

0.86 (0.57-1.30)

.47

Comorbidities (in addition to CRC): ≥2 comorbidities (reference, 0 or 1
comorbidities)

0.86 (0.64-1.17)

.35

Adult caregiving: provides care for at least 1 spouse, parent, parent-in-law,
adult relative, or friend who lives in the participant’s home (reference,
does not provide caregiving for another adult)

0.94 (0.62-1.43)

.78

Sources of social supportb
Coworkers (reference, none, a little, some, does not apply, or missing)

2.60 (1.70-3.98)

<.001

Health care practitioners (reference, none, a little, some, does not apply, or
missing)

1.97 (1.45-2.68)

<.001

Friends (reference, none, a little, some, does not apply, or missing)

1.83 (1.32-2.55)

<.001

Spouse or partner (reference, none, a little, some, does not apply, or missing)

1.73 (1.25-2.38)

.001

Family members (excluding spouse or partner) (reference, none, a little, some,
does not apply, or missing)

1.63 (1.10-2.41)

.02

Members of religious community (reference, none, a little, some, does not apply,
or missing)

1.30 (0.96-1.76)

.09

Other people with CRC (reference, none, a little, some, does not apply, or missing)

1.25 (0.85-1.82)

.26
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a

Results based on multivariable logistic regression
models adjusted for age, sex, race, and study site.

b

Social support was categorized as high (quite a bit or
a lot) vs low (none, a little, some, does not apply, or
not reported).
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with CRC with either one of these social risk factors, whereas no racial disparities in chemotherapy
receipt were evident among patients with private health insurance living in lower-poverty
neighborhoods.
In another study,44 no difference was observed in chemotherapy receipt between unmarried
and married women with CRC who lived in lower-poverty neighborhoods and had private health
insurance. However, among women living in higher-poverty neighborhoods with inadequate health
insurance, unmarried women were 26% less likely to receive chemotherapy than married women.44
This finding was consistent with our finding that single marital status was associated with decreased
chemotherapy receipt.
Among patients without adequate insurance living in high-poverty neighborhoods,
chemotherapy receipt was almost 60% lower among Black patients than White patients,43
suggesting a multiplicative association of social disadvantage on chemotherapy receipt. These
findings are generally consistent with the results of the current study, in that lower income was
associated with reduced likelihood of completing chemotherapy and that Black patients with CRC
were more likely to have both higher cumulative social risk and fewer sources of social support to
mitigate the health associations of cumulative social risk.
Caleyachetty and colleagues42 found that higher cumulative social risk exposure (defined as low
education, low income, socioeconomically disadvantaged race/ethnicity, and lacking a spouse or
partner) was associated with higher all-cancer mortality, and income played a particularly important
role. Related research45,46 has observed positive associations between other constructions of
cumulative social risk and all-cause mortality. These previous studies, in combination with our
findings, indicate that although certain social risk factors play a more prominent role, the combined
effect of coping with multiple social risk factors concurrently increases the risk that patients with CRC
will not undergo chemotherapy treatment as recommended by their health care team.

Limitations
This study has several limitations, including a reliance on self-reported data and the possibility of
recall bias or misremembering timing of events, which may have reduced the validity of data
obtained from retrospective questions. We mitigated the potential for inaccurate recall in 3 ways,
including references to memorable, highly salient events in the question stem, deploying the survey
shortly after diagnosis, and limiting the time span during which returned surveys were accepted.
Although it is possible that study respondents made errors when answering these questions, we
found the expected distribution of responses and have no reason to believe that the data were
adversely impacted by recall bias.
In the absence of previous literature to provide conceptual guidance for our analytical decisions,
we weighted social risks equally a priori; however, investigators in future studies of CRC treatment
may wish to use the current findings to construct a weighted measure of social risk. We also note that
social support was measured using a scale that only assessed emotional support, and, thus, other
types of social support (eg, informational, instrumental, and appraisal support) were not reflected in
the current analyses. These additional types of social support may be particularly associated with
the ability of patients with CRC with high social risk to undergo their CRC treatment as prescribed by
their doctors. Although these additional forms of social support were not available in the present
data set, they should be included in future research.
Furthermore, the inclusion of stage III colon and rectal cancer from only 2 SEER catchment areas
may limit generalizability of our findings. However, the sampling strategy also represents a strength
of the study, in that these sites were located in 2 different regions of the US and included a racially
diverse sample. We attempted to mitigate nonresponse bias with additional analyses that weighted
study responses with SEER site-reported demographic data.
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Conclusions
The findings of this study have at least 4 important clinical implications. First, patients with advanced
CRC were less likely to receive chemotherapy as their cumulative social risk increased. This
information can be used to identify those patients most at risk for omitting chemotherapy for
nonclinical reasons, who can be targeted with patient support programs to address their
individualized risk factors, such as help interpreting health information or connecting patients to
financial resources. Second, patients with multiple social risk factors may need more holistic patient
support programs to undergo their recommended chemotherapy treatment, as opposed to
programs that only address isolated social risk factors. Third, social support matters. As in previous
research, findings from this study indicated that access to adequate social support minimized the
association of social disadvantage with health outcomes. However, this study also found that support
from almost any source may be helpful. Although support from family and friends was expected to
be beneficial, data from this study indicated that programs to help working patients with CRC obtain
support from coworkers may be even more helpful in increasing chemotherapy receipt. Fourth, even
for patients with social support, the risk that they would not undergo chemotherapy increased as
social risk factors accumulated. Thus, although the availability of social support appeared to be a
critical resource for encouraging chemotherapy receipt, patients with multiple social risk factors with
social support were still at higher risk of not completing chemotherapy treatment, and, as a
consequence, adverse long-term outcomes.
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